Format

Send to

Choose Destination
Drug Discov Today. 2013 Jan;18(1-2):43-9. doi: 10.1016/j.drudis.2012.07.013. Epub 2012 Aug 3.

The development and application of small molecule modulators of SF3b as therapeutic agents for cancer.

Author information

1
Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.

Abstract

The identification of potent spliceosome modulators that demonstrate antitumor activity indicates that this complex may be a target for drug development. Several natural products have been demonstrated to bind to the SF3b1 subunit of this macromolecule and these agents modulate alternative RNA splicing. In this article we describe their biological properties, discuss the validity of the spliceosome as a therapeutic target, and propose that alteration of alternative splicing represents a viable approach for inducing tumor-selective cytotoxicity.

PMID:
22885522
PMCID:
PMC3596818
DOI:
10.1016/j.drudis.2012.07.013
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center